Search

Your search keyword '"Albera, C."' showing total 271 results

Search Constraints

Start Over You searched for: Author "Albera, C." Remove constraint Author: "Albera, C."
Sorry, I don't understand your search. ×
271 results on '"Albera, C."'

Search Results

2. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

3. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

5. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

7. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study

10. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study

12. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

13. Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good

15. Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016

17. The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone

18. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis

20. Malattie infiltrative diffuse del polmone

21. Italian Cystic Fibrosis Registry. Report 2011-2014

22. The Diagnosis of Interstitial Lung Disease: Comparison Between HRTC Appearance and Histological Pattern

24. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist

25. The AIPO-SIMeR document on idiopathic pulmonary fibrosis

26. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.

27. Supplementary Material for: An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)

28. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

32. The AIPO-SIMeR document on idiopathic pulmonary fibrosis

37. Building Bridges for Innovation in Ageing : Synergies between Action Groups of the EIP on AHA

38. Building bridges for innovation in ageing:synergies between action groups of the EIP on AHA

39. Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

40. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

41. BUILDING BRIDGES FOR INNOVATION IN AGEING: SYNERGIES BETWEEN ACTION GROUPS OF THE EIP ON AHA

42. Building Bridges for Innovation in Ageing:Synergies between Action Groups of the EIP on AHA

43. Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA

44. Malattie infiltrative diffuse del polmone

45. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

46. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

47. Italian Cystic Fibrosis Register - Report 2010

48. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

Catalog

Books, media, physical & digital resources